Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
Described are compositions and methods relating to gene therapy, particularly as applied to hematopoietic progenitor (HP) cells, to transduced cells and methods of obtaining them, and to methods of using them to provide prolonged engraftment of modified hematopoietic cells in human subjects. The invention particularly relates to ex vivo gene therapy of HP cells for treatment or prevention of HIV infection.
1. A composition for engraftment of transduced autologous CD34 + hematopoietic progenitor cells in a human subject which comprises a pharmaceutically acceptable carrier and a minimum dose of 0.52×10 6 transduced CD34 + hematopoietic progenitor cells per kg body weight of the subject in a total CD34 + cell population of at least 1.63×10 6 CD34 + hematopoietic progenitor cells per kg body weight of the subject, the transduced cells comprising a RRz2 vector encoding a ribozyme and the number of transduced cells being determinable by performing competitive PCR on such transduced CD34 + hematopoietic cells, wherein the ribozyme is encoded by DNA nucleotides having the sequence 5′-TTA GGA TCC TGA TGA GTC CGT GAG GAC GAA ACT GGC TC-3′ (SEQ ID NO: 3).
2. The composition of claim 1 , comprising a minimum dose of 5×10 6 transduced CD34 + hematopoietic progenitor cells per kg body weight of the subject in a total CD34 + cell population comprising 9.37×10 6 CD34 + hematopoietic progenitor cells per kg body weight of the subject.
3. The composition of claim 1 , wherein the CD34 + hematopoietic progenitor cells are from mobilized peripheral blood of the subject.
4. The composition of claim 1 , wherein the cells are transduced in the presence of an agent that enhances co-localization of the cells with a viral construct.
5. The composition of claim 4 , wherein the agent is a recombinant fragment of fibronectin.
6. The composition of claim 5 , wherein the recombinant fragment of fibronectin is the CH296 fragment of human fibronectin.
7. The composition of claim 2 , wherein the CD34 + hematopoietic progenitor cells are from mobilized peripheral blood of the subject.
8. The composition of claim 2 , wherein the cells are transduced in the presence of a CH296 fragment of human fibronectin.
9. The composition of claim 3 , wherein the cells are transduced in the presence of a CH296 fragment of human fibronectin.
10. The composition of claim 7 , wherein the cells are transduced in the presence of a CH296 fragment of human fibronectin.
11. The composition of claim 1 , wherein the composition is substantially free of cytokines.
12. The composition of claim 1 , wherein the composition is substantially free of virus.
13. The composition of claim 1 , wherein in the subject the transduced CD34 + hematopoietic progenitor cells give rise to progeny cells for at least 12 months.
14. A composition for engraftment of transduced autologous CD34 + hematopoietic progenitor cells in a human subject which comprises a pharmaceutically acceptable carrier and a minimum dose of 0.5×10 6 transduced CD34 + hematopoietic progenitor cells per kg body weight of the subject in a total CD34 + cell population of at least 1.7×10 6 CD34 + hematopoietic progenitor cells per kg body weight of the subject, the transduced cells comprising a RRz2 vector encoding a ribozyme and the number of transduced cells being determinable by performing competitive PCR on such transduced CD34 + hematopoietic cells, wherein the ribozyme is encoded by DNA nucleotides having the sequence 5′-TTA GGA TCC TGA TGA GTC CGT GAG GAC GAA ACT GGC TC-3′ (SEQ ID NO: 3).
15. The composition of claim 14 , comprising a minimum dose of 5×10 6 transduced CD34 + hematopoietic progenitor cells per kg body weight of the subject.
16. The composition of claim 14 , wherein the CD34 + hematopoietic progenitor cells are from mobilized peripheral blood of the subject.
17. The composition of claim 14 , wherein the cells are transduced in the presence of an agent that enhances co-localization of the cells with a retroviral construct.
18. The composition of claim 17 , wherein the agent is a CH296 fragment of human fibronectin.